Table 1 Characteristics of the included cohort studies
Studies | Year | Study design | Country | Intervention(TDF/ETV) | Age, Mean (SD)(TDF/ETV) | Sample size (TDF/ETV) | Follow-up time (weeks) | Outcome |
|---|---|---|---|---|---|---|---|---|
Hossain et al. [17] | 2021 | Prospective cohort | Bangladesh | 300 mg/d 0.5 mg/d | 43.8 ± 13.1 44.2 ± 12.3 | 16/16 | 12 | ①Survival rate ② HBV-DNA clearance rate ③CTP score ④MELD score |
Zhang et al. [13] | 2020 | Prospective cohort | China | NR | 44.33 ± 15.87 45.97 ± 14.10 | 39/39 | 24 | ①Survival rate ② HBV-DNA levels ③Serum surface antigen conversion |
Zhang et al. [16] | 2021 | Prospective cohort | China | 300 mg/d 0.5 mg/d | 38.87 ± 7.95 43.90 ± 9.91 | 23/42 | 24 | ①Survival rate ② HBV-DNA clearance rate ③Serum surface antigen conversion ④MELD score ⑤Safety |
Li et al. [14] | 2021 | Prospective cohort | China | 300 mg/d 0.5 mg/d | 41 ± 12.64 39.72 ± 9.13 | 10/20 | 48 | ①Survival rate ②HBV-DNA levels ③MELD score ④Safety |
Wan et al. [15] | 2019 | Retrospective cohort study | China | 300 mg/d 0.5 mg/d | 43.54 ± 11.13 50.71 ± 10.7 | 32/35 | 12 | ①Survival rate ②HBV-DNA levels ③HBV DNA clearance rate ④Serum surface antigen conversion ⑤CTP score ⑥MELD score ⑦Safety |